SCHEMBL6437644

SCHEMBL6437644

CCOC(=O)c1ccc2c(Cl)cnc(Cl)c2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
RAB9A P51151 3/20 0.51
NPC1 O15118 2/20 0.51
CYP1A2 P05177 2/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
CA12 O43570 2/20 0.48
CA1 P00915 2/20 0.48
CA2 P00918 2/20 0.48
CA7 P43166 2/20 0.48
CA9 Q16790 2/20 0.48
CA14 Q9ULX7 2/20 0.48
HCRTR1 O43613 2/20 0.47
KDM4E B2RXH2 5/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
MAPT P10636 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MAPK1 P28482 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13754214 0.79 ALDH1A1 (0.42) ALDH1A1RAB9ANPC1KDM4EMEN1
SCHEMBL2671190 0.78 ALDH1A1 (0.53) ALDH1A1L3MBTL1RAB9ANPC1CYP1A2
SCHEMBL1680503 0.78 ALDH1A1 (0.56) ALDH1A1L3MBTL1RAB9ANPC1CYP1A2
SCHEMBL2671291 0.78 ALDH1A1 (0.50) ALDH1A1L3MBTL1RAB9ANPC1CYP1A2
SCHEMBL6433263 0.77 PLAU (0.42) RAB9ANPC1MEN1KMT2AMAPK1
SCHEMBL6433486 0.77 PLAU (0.51) ALDH1A1L3MBTL1MAPTHPGDPOLB
SCHEMBL6434323 0.76 PLAU (0.51) ALDH1A1L3MBTL1RAB9ANPC1CYP1A2
SCHEMBL31050105 0.76 ALDH1A1 (0.61) ALDH1A1L3MBTL1CYP2C9CYP2C19CA12
SCHEMBL337203 0.76 ALDH1A1 (0.61) ALDH1A1L3MBTL1CYP2C9CYP2C19CA12
SCHEMBL16110055 0.76 KDM4E (0.58) ALDH1A1L3MBTL1RAB9ANPC1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1077945-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER (US) 2003-01-08 EP disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 EP disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 WO disclosed
EP-1077945-A1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2001-02-28 EP disclosed
US-6093731-A Isoquinolines PFIZER INC. 2000-07-25 US disclosed
WO-2000005214-A2 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2000-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 ALDH1A1 2641/4885L3MBTL1 2500/4885RAB9A 3609/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 ALDH1A1 2641/4885L3MBTL1 2500/4885RAB9A 3609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.